Theriva Biologics, Inc.

Synthetic Biologics, Inc.

Christian Furlan Freguia

Michael Kaleko

Sheila Connelly

Vincent Wacher

J Blair West

Andrew Bristol

Steven Hubert

Ray Stapleton

Cristina Freire

James Gubbins

Vincent J Watcher

Blair J West

The present invention relates to methods and compositions for preventing, treating, or reducing chemotherapy treatment-mediated side effects, including gastrointestinal (GI) side effects, comprising administering to a subject intestinal alkaline phosphatases (IAP).

Alkaline phosphate-based oncology treatments

The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.

Alkaline phosphatase formulations

The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.

Alkaline phosphatase agents for treatment of radiation disorders

The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.

Intestinal alkaline phosphatase formulations

Compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders, are described.

Growing community of inventors

Rockville, MD, United States of America

Christian Furlan Freguia